Paradigm Biocapital Advisors LP Tarsus Pharmaceuticals, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $2.77 Billion
- Q3 2024
A detailed history of Paradigm Biocapital Advisors LP transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 2,440,445 shares of TARS stock, worth $133 Million. This represents 2.89% of its overall portfolio holdings.
Number of Shares
2,440,445
Previous 2,435,416
0.21%
Holding current value
$133 Million
Previous $66.2 Million
21.26%
% of portfolio
2.89%
Previous 2.68%
Shares
4 transactions
Others Institutions Holding TARS
# of Institutions
170Shares Held
43.3MCall Options Held
484KPut Options Held
4.1K-
Rtw Investments, LP New York, NY3.41MShares$186 Million1.79% of portfolio
-
Black Rock Inc. New York, NY3.27MShares$178 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.25MShares$123 Million6.32% of portfolio
-
Morgan Stanley New York, NY2.21MShares$120 Million0.01% of portfolio
-
Cowen And Company, LLC2.2MShares$120 Million1.86% of portfolio
About Tarsus Pharmaceuticals, Inc.
- Ticker TARS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,658,500
- Market Cap $1.45B
- Description
- Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...